In the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

Replace the paragraph [0052] beginning at page 31 with the following rewritten paragraph:

In another aspect, the invention features a nucleic acid that includes a coding sequence that encodes a polypeptide comprising an immunoglobulin heavy chain variable domain that binds to CD44, e.g., an immunoglobulin heavy chain variable domain described herein. For example, the immunoglobulin heavy chain variable domain can include: (a) a CDR1 sequence motif comprising X_1-Y-X_2-M-X_3 (SEQ ID NO:[[___]] **98**), wherein X_1 is E, L or P, X_2 is G, R, or L, and X_3 is G, R, or S, (b) a CDR2 sequence comprising: S-I-X_1-X_2-S-G-G-X_3-T-X_4-Y-A-D-S-V-K-G **(SEQ ID NO:99)**, where X_1 is any amino acid, X_2 is any amino acid, X_3 is hydrophobic, and X_4 is any amino acid, and/or (c) a CDR3 sequence comprising one of the following exemplary sequences: DVGVGAAD (SEQ ID NO:[[___]] **100**), DGYYDSSGYEGFD (SEQ ID NO:[[___]] **101**), and GTRTVT (SEQ ID NO:[[___]] **108**). In another example, the immunoglobulin heavy chain variable domain can include: a HC CDR_1 sequence motif comprising X_1-Y-X_2-M-X_3 (SEQ ID NO: [[___]] **98**), wherein X_1 is any amino acid (e.g., E, L, K, H, N, W, or P), X_2 is any amino acid (e.g., G, R, S, T, or L), and X_3 is any amino acid (e.g., G, R, W, M, N, D, E, or S); a HC CDR_2 sequence comprising: X_1-I-X_2-X_3-X_4-G-G-X_5-T-X_6-Y-A-D-S-V-K-G (SEQ ID NO:[[___]] **99**), where X_1 is any amino acid (e.g., S or R); X_2 is any amino acid (e.g., V, S, Y, W, F, V, G, or S), X_3 is any amino acid (e.g., S or P), X_4 is S or absent, X_5 is hydrophobic (e.g., F, I, L, W, or P) or Q or T, and X_6 is any amino acid (e.g., F, E, D, R, L, or K); and/or a HC CDR3 sequence comprising one of the following exemplary sequences: DVGVGAAD (SEQ ID NO: [[___]] **100**), DGYYDSSGYEGFD (SEQ ID NO: [[___]] **101**), RSGSYPAD (SEQ ID NO: [[___]] **102**), DRAAA (SEQ ID NO: [[___]] **103**), GWSSQPA (SEQ ID NO: [[___]] **104**), DYYDSSGYSYFD (SEQ ID NO: [[___]] **105**), QKRSSLGAFD (SEQ ID NO:[[___]] **106**), DSYGMD (SEQ ID NO: [[___]] **107**) and GTRTVT (SEQ ID NO:[[___]] **108**), or a sequence that is at least 85% identical to one of the foregoing. The immunoglobulin

heavy chain variable domain can include a framework region described herein. In one example, the variable domain is a heavy chain variable domain is at least 75, 80, 85, 90, 92, 95, 96, 97, 98, or 99% identical to a heavy chain variable domain of an antibody described herein, e.g., BE-B12, BE-D7, HAE-B8, HAE-F1, BE-A11, F2, HAE-H10, HAE-H-H10, H1, HAE-A3, BE-H10, HAE-H9, or HAE-G.

Replace the paragraph [0053] beginning at page 32 with the following rewritten paragraph:

In another aspect, the invention features a nucleic acid that includes a coding sequence that encodes a polypeptide comprising an immunoglobulin light chain variable domain that binds to CD44, e.g., an immunoglobulin light chain variable domain described herein. For example, the immunoglobulin light chain variable domain can include: (a) a CDR1 comprising an amino acid sequence of at least 13amino acids of which at least 11 amino acids are identical to RSSQSLLHSNGYNYLD (SEQ ID NO: [[___]] **122**); (b) a CDR2 comprising an amino acid sequence of at least 7 amino acids of which at least 5 amino acids are identical to LGSNRAS (SEQ ID NO:[[___]] **123**); and/or (c) a CDR3 comprising M-Q-A-L-Q-X1-P-X2-T (SEQ ID NO: [[___]] **124**), where X1 is any amino acid or no amino acid, and X2 is any amino acid (e.g., hydrophobic, R, or Y) or absent.